Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer
暂无分享,去创建一个
[1] J P Donohue,et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D. Tait,et al. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. , 1984, British Journal of Cancer.
[3] H. Brachinger,et al. Decision analysis , 1997 .
[4] A. Horwich,et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Boetes,et al. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. , 1990, British journal of urology.
[6] Richard Sylvester,et al. International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .
[7] J. Habbema,et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Ulbright,et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Habbema,et al. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. , 1994, European journal of cancer.
[10] E. Steyerberg,et al. Postchemotherapy surgery in nonseminoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Baldetorp,et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Horwich,et al. Ejaculatory dysfunction after retroperitoneal lymphadenectomy. , 1993, European urology.
[13] L. Einhorn,et al. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction , 1981, Cancer.
[14] D. Dearnaley,et al. Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. , 1993, British journal of urology.
[15] R. Ravi. Growing teratoma syndrome. , 1995, Urologia internationalis.
[16] O. Nativ,et al. The malignant potential of postchemotherapy residual mature teratoma for disseminated nonseminomatous testicular tumors. , 1994, European urology.
[17] L. Einhorn. Treatment of testicular cancer: a new and improved model. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Habbema,et al. Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. , 1996, British Journal of Cancer.
[19] L. Einhorn,et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] C. Cornelisse,et al. Karyotyping and DNA flow cytometry of mature residual teratoma after intensive chemotherapy of disseminated nonseminomatous germ cell tumor of the testis: a report of two cases. , 1986, Cancer genetics and cytogenetics.
[21] D. Sleijfer,et al. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin‐vinblastine‐bleomycin chemotherapy , 1988, Journal of surgical oncology.
[22] N. Geller,et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Fasoli. [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.
[24] J. Habbema,et al. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. , 1993, British Journal of Cancer.
[25] K. Sikora. Testicular Cancer-Investigation and Management , 1993, British Journal of Cancer.
[26] W. Hendry. Decision making in abdominal surgery following chemotherapy for testicular cancer. , 1995, European journal of cancer.
[27] W. Molenaar,et al. Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. , 1997, British journal of urology.
[28] R. Motzer,et al. Testicular germ-cell cancer. , 1997, The New England journal of medicine.
[29] S. Fosså,et al. Psychosocial well-being in testicular cancer patients. , 1991, European Journal of Cancer.
[30] S. Fosså,et al. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] K. Kopecky,et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. , 1987, The Journal of urology.